|1.||Cheville, John C: 20 articles (12/2013 - 04/2002)|
|2.||Lohse, Christine M: 19 articles (12/2013 - 04/2002)|
|3.||Leibovich, Bradley C: 18 articles (02/2015 - 04/2003)|
|4.||Blute, Michael L: 17 articles (06/2010 - 04/2002)|
|5.||Nagashima, Yoji: 11 articles (08/2014 - 05/2002)|
|6.||Zincke, Horst: 11 articles (11/2005 - 04/2002)|
|7.||Kwon, Eugene D: 10 articles (02/2015 - 04/2003)|
|8.||Pantuck, Allan J: 9 articles (02/2015 - 09/2004)|
|9.||Yao, Masahiro: 9 articles (08/2014 - 05/2002)|
|10.||Kishida, Takeshi: 9 articles (08/2014 - 05/2002)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
04/01/2015 - "Systemic treatments for patients with renal cell carcinoma (RCC) tend to be significantly less effective for non-clear cell RCC, with lower response rates and worse progression-free survival and overall survival when compared with clear cell RCC. "
10/01/2009 - "Through systemic examination of FADD in renal cell carcinoma (RCC) and adjacent nontumor kidney tissues from 85 patients, we demonstrated a significant reduction of FADD in clear cell RCC (ccRCC) compared to the respective nontumor kidney tissues. "
12/01/2015 - "Cystic renal cell carcinoma (cystic RCC) is thought to carry an improved prognosis relative to clear cell RCC (CCRCC); however, this is based on small case series. "
05/01/2015 - "The objective of our study was to determine whether CT findings, including texture analysis, can differentiate sarcomatoid renal cell carcinoma (RCC) from clear cell RCC. "
11/01/2012 - "The objective of this study was to evaluate EZH2 expression in renal cell carcinoma (RCC), especially clear cell RCC (CRCC) and correlate the expression with prognostic factors. "
07/01/2015 - "The study used the DoD's Automated Central Tumor Registry to identify 2056 White patients and 370 Black patients diagnosed with clear cell RCC between 1988 and 2004. "
01/01/2014 - "The positive predictive value was higher for clear cell RCC than for papillary or chromophobe RCC, suggesting that pathologic confirmation may be warranted for studies of non-clear cell tumors."
12/01/2013 - "Following institutional review board approval, the study evaluated 2180 patients who had been surgically treated for clear-cell RCC between 1985 and 2006 who had data available on three tumor dimensions. "
07/01/2012 - "In this study, PF, location of tumor, and age were significant predictors of clear-cell RCC histopathology. "
05/01/2011 - "The identification of loss of function of the von Hippel-Lindau protein as the basis for clear cell RCC, in addition to the well designed clinical trials that have ensued, provide an outstanding model for the development of mechanism-based targeted therapy in cancer. "
|3.||Neoplasm Metastasis (Metastasis)
06/01/2013 - "In conclusion, our study suggests that negative expression of metastin receptor in clear cell RCC is significantly related to metastasis."
01/01/2015 - "A total of 521 patients participated, including 40% aged ≥65 years, 11% with an Eastern Cooperative Oncology Group performance status ≥2, 14% with non-clear cell RCC, and 11% with brain metastases. "
01/01/2015 - "HDAC10 expression is suppressed in human clear cell RCC and is involved in development and metastasis of RCC. "
12/01/2014 - "Taken altogether, increased expression of CHI3L1 and MVD is associated with metastasis and a worse prognosis in clear cell RCC. "
02/01/2014 - "Based on the histological and immunohistochemical features, the patient was diagnosed with metastasis of clear cell RCC to the breast IDC. "
|4.||Oxyphilic Adenoma (Oncocytoma)
05/01/2013 - "Thresholding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accuracies of 77% (83 of 108 cases), 85% (101 of 119 cases), and 84% (81 of 97 cases). "
09/01/2015 - "Our study suggests that clear cell RCC has the thickest pseudocapsule while oncocytoma has a poorly developed pseudocapsule, but shows the least infiltrative pattern. "
11/01/2014 - "Clear cell RCC had greater deenhancement than oncocytoma (p < 0.001); deenhancement less than 50 HU or relative corticomedullary attenuation greater than 0% differentiated clear cell RCC from oncocytoma with a positive predictive value of 90%. "
08/01/2013 - "Pax-2 is commonly expressed in the most prevalent renal cell tumour (RCT) subtypes-clear cell RCC (ccRCC), papillary RCC (pRCC) and oncocytoma--but not in chromophobe RCC (chrRCC), which frequently displays chromosome 10 loss (to which PAX2 is mapped). "
05/01/2013 - "Enhancement at multiphasic multidetector CT, if prospectively validated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC."
06/01/2013 - "Median chemical shift index was significantly greater in clear cell RCC and angiomyolipoma than in the other histological subtypes (both, P < 0.001). "
01/01/2016 - "Establishment of threshold enhancement values helped to differentiate clear cell RCC from papillary RCC, chromophobe RCC, and fat-poor angiomyolipoma with the following accuracies: percentage enhancement ratio, 84.7% (399/471) for papillary RCC, 71.1% (325/457) for chromophobe RCC, and 81.9% (377/460) for fat-poor angiomyolipoma; enhancement change, 80.9% (381/471) for papillary RCC, 70.2% (321/457) for chromophobe RCC, and 80.6% (371/460) for fat-poor angiomyolipoma; absolute washout ratio, 88.5% (417/471) for papillary RCC, 74.1% (339/457) for chromophobe RCC, and 85.0% (391/460) for fat-poor angiomyolipoma. "
01/01/2016 - "Quantitative enhancement measurement may be useful for differentiating clear cell RCC from papillary RCC, chromophobe RCC, and fat-poor angiomyolipoma."
12/01/2014 - "Mean attenuation of minimal-fat angiomyolipoma was 43.1±9.8 HU, which was significantly higher when compared with RCC overall (p=0.004) as well as with clear cell RCC (33.1±10.2 HU; p=0.003), papillary RCC (33.0±6.6 HU; p=0.003), and chromophobe RCC (34.3±9.9 HU; p=0.01). "
11/01/2014 - "Four-phase MDCT renal attenuation profiles enable differentiation of clear cell RCC from other solid renal cortical masses, most notably papillary RCC and lipid-poor angiomyolipoma."
|1.||sorafenib (BAY 43-9006)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Messenger RNA (mRNA)
|9.||Carbonic Anhydrases (Carbonic Anhydrase)
|4.||Molecular Targeted Therapy